Compare CLPS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | IGC |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 32.0M |
| IPO Year | 2017 | 2005 |
| Metric | CLPS | IGC |
|---|---|---|
| Price | $0.81 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 465.4K |
| Earning Date | 10-16-2026 | 11-06-2026 |
| Dividend Yield | ★ 14.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.08 |
| 52 Week High | $1.24 | $0.37 |
| Indicator | CLPS | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 32.51 |
| Support Level | $0.86 | $0.08 |
| Resistance Level | $0.95 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 31.58 | 62.09 |
CLPS Inc is information technology, consulting and solutions service provider, focused on delivering services mainly to world-wide institutions, including banking, wealth management, ecommerce, and automotive areas both in China and globally. It has been at the forefront of driving digital transformation and optimizing operational efficiency across industries through innovations in artificial intelligence (AI), cloud computing, and data. It diverse business lines span sectors including fintech, payment and credit services, e-commerce, education and study abroad programs, and world-wide tourism integrated with transportation services. Its segments are IT services and academic education service. Majority of revenue comes from IT services segment. Its products are NiBot RPA, and CAKU.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.